Evolus, Inc. $EOLS Position Cut by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 85.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,402 shares of the company's stock after selling 62,206 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Evolus were worth $96,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. AlphaQuest LLC acquired a new position in Evolus during the 1st quarter valued at about $39,000. State of Wyoming boosted its position in shares of Evolus by 988.1% during the first quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares during the period. Versor Investments LP acquired a new position in shares of Evolus during the second quarter worth approximately $102,000. IFP Advisors Inc grew its holdings in Evolus by 99.0% in the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock worth $113,000 after buying an additional 4,691 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Evolus in the 1st quarter valued at approximately $151,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Trading Up 3.5%

NASDAQ:EOLS opened at $6.85 on Friday. The company has a 50-day moving average of $6.57 and a 200-day moving average of $8.06. The firm has a market cap of $444.02 million, a price-to-earnings ratio of -7.45 and a beta of 0.97. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.12.

Evolus (NASDAQ:EOLS - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. Evolus has set its FY 2025 guidance at EPS. On average, research analysts forecast that Evolus, Inc. will post -0.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EOLS. HC Wainwright reduced their price target on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC reiterated a "hold" rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Evolus from a "sell" rating to a "hold" rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Evolus in a research note on Monday. Finally, BTIG Research reiterated a "buy" rating and issued a $18.00 price objective on shares of Evolus in a report on Monday, September 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $21.25.

Check Out Our Latest Analysis on EOLS

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Stories

• Five stocks we like better than Evolus
• Best ESG Stocks: 11 Best Stocks for ESG Investing
• A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
• What Are Trending Stocks? Trending Stocks Explained
• 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
• What is a Special Dividend?
• Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?

Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Evolus Right Now?

Before you consider Evolus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.

While Evolus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here